CANbridge Announces Expansion of LIVMARLI® Label to Include Patients as Young as 3 Months in China

May 21, 2024

CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2023

Mar 28, 2024

CANbridge and PUMCH announced the establishment of PUMCH- CANbridge Genetic Defect Rare Disease Innovation and Translation Base

Mar 01, 2024

Livmarli mentioned as a case study The Policy Address highlights Hong Kong's strengths in research and development, emphasizing its capcity to independently approve new drugs Rare disease drugs will receive significant benefits  

Nov 15, 2023

Foundation consolidated over time and for a rosy future | 2023 China Conference on Rare Diseases closed successfully

Nov 06, 2023

CANbridge Pharmaceuticals to Present Fabry Disease Gene Therapy Abstract at ESGCT 30th Annual Congress

Oct 25, 2023

CANbridge Announces NDA Acceptance of CAN108 (邁芮倍®/LIVMARLI®) for Cholestatic Pruritus in Progressive Familial Intrahepatic Cholestasis (PFIC) by China’s National Medical Products Administration

Oct 17, 2023

CANbridge Announces Full Enrollment Reached in the Core Part of The CAN103 Phase 2 Trial for Gaucher Disease in China

Oct 16, 2023

CANbridge Announces Marketing Approval of CAN108 (邁芮倍®/LIVMARLI®) in Taiwan for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)

- LIVMARLI is the First and Only Treatment Approved in Taiwan for Cholestatic Pruritus in ALGS

- LIVMARLI is approved for Cholestatic Pruritus in ALGS in the US, Canada, Europe, Mainland China, and other regions globally

Oct 09, 2023

CANbridge Announces Marketing Approval of CAN108 (LIVMARLI®) in Hong Kong for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome (ALGS)

- LIVMARLI is the First and Only Treatment Approved in Hong Kong for Cholestatic Pruritus in ALGS

- LIVMARLI is approved for Cholestatic Pruritus in ALGS in the United States, Canada, Europe, Mainland China and other regions globally

Sep 28, 2023

CANbridge Pharmaceuticals Fabry Disease Gene Therapy Abstract Accepted by ESGCT 30th Annual Congress Presentation

Sep 28, 2023

Policy News | “Second List of Rare Diseases” Published: A Pivotal Milestone in China’s Healthcare with 86 Rare Diseases Listed

Sep 21, 2023

CANbridge to Participate in Two Investor Conferences in September

Sep 06, 2023

CANbridge Announces Interim Financial Results and Corporate Updates for the Six Months Ended June 30, 2023

Sep 04, 2023

CANbridge to Continue CAN008 Phase 2 Trial in Glioblastoma Multiforme (GBM) in China Based on Interim Analysis of Independent Data Monitoring Committee

Jul 03, 2023

CANbridge Reports Positive Preliminary Data in the Omoprubart (CAN106) Phase 1b Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

-Promising Efficacy and Safety with Four-Week Extended Dosing

-Data Shows Dose-Dependent Reduction of LDH and Increased Hemoglobin Levels that Demonstrate Clinically Meaningful Hemolysis Inhibition

-CANbridge Plans to Advance to Pivotal Trial

-CANbridge to Hold Investor Call

Jun 25, 2023

CANbridge Announces Marketing Approval of CAN108 (迈芮倍®/LIVMARLI®) in China for the Treatment of Cholestatic Pruritus in Patients with Alagille Syndrome

-LIVMARLI First and Only Treatment Approved in Mainland China for Cholestatic Pruritus in ALGS

-CANbridge to Hold Investor Call

Jun 01, 2023

CANbridge to Participate in the Jefferies 2023 Global Healthcare Conference

May 31, 2023

CANbridge Announces Full Enrollment Reached in China Region of the Global LIVMARLI® (CAN108) EMBARK Phase 2 Study in Biliary Atresia

May 30, 2023

CANbridge and UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy (CAN203) Improves Lifespan and Motor Function in Mice When Administered via Intracerebroventricular Injection

-Data Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

May 17, 2023

CANbridge Pharmaceuticals Appoints Jason West Vice President, Head of Gene Therapy Research

May 06, 2023

CANbridge-UMass Chan Medical School Spinal Muscular Atrophy Gene Therapy Animal Data to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

-Novel Second-Generation SMA Gene Therapy Rescues Motor Function in Mice,  Outperforms Benchmark Therapy

May 05, 2023

CANbridge Pharmaceuticals Spinal Muscular Atrophy Gene Therapy Abstract Accepted for Presentation at the American Society for Gene and Cell Therapy Annual Meeting

Apr 13, 2023

CANbridge Announces Financial Results and Corporate Updates for Twelve Months Ended December 31, 2022

Mar 30, 2023

CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China Reaches Full Enrollment

-Recent CAN008 Phase 1 Follow-Up Data Showed 67% 5-Year Overall Survival in High-Dose Cohort, Reported at ESMO Sarcoma and Rare Cancers

Mar 28, 2023

Long-Term Data from CANbridge Pharmaceuticals CAN008 Phase 1/2 Trial in Glioblastoma Multiforme Shows 67% Five-Year Overall Survival Rate Compared to 8.2% in Institutional Database

-Data to be Presented at the ESMO Sarcoma and Rare Cancers Annual Congress

-83% overall survival at two years vs. 34.3% OS from institutional database

-17.95 months median progression-free survival vs. 5.8 months PFS in historical group

Mar 17, 2023

CANbridge Pharmaceuticals Announces CAN008 Phase 1/2 Glioblastoma Multiforme Abstract Accepted by the ESMO Sarcoma and Rare Cancers Congress

Mar 13, 2023

CANbridge Named to South Reviews “2022 Annual List of Chinese Social Values”

Feb 24, 2023

Article from Cloud-based Medicine Studio | A national authoritative medical organization for rare diseases will be established, and the second list of rare diseases will be updated
(attachments: the first list and the national reimbursement drug list)

Jan 31, 2023

First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 2 Trial for the Treatment of Gaucher Disease in China

Jan 18, 2023

CANbridge Congratulates Apogenix on First Patient Dosed in Asunercept (CAN008) Phase 3 Trial for the Treatment of COVID-19

-CANbridge holds exclusive rights for the development of CAN008 for any indication in Greater China

-CAN008 currently in Phase 2 trial for the treatment of glioblastoma multiforme in China

Jan 05, 2023

CANbridge Consolidates Gene Therapy Portfolio

-Secures Exclusive Global Rights to Potentially Best-in-Class Spinal Muscular Atrophy Gene Therapy from UMass Chan Medical School

-Completes Technology Transfer of Two Gene Therapies for Lysomal Storage Diseases

Jan 04, 2023

CANbridge Congratulates Mirum on EU Marketing Approval for  Maralixibat/LIVMARLI® to Treat Cholestatic Pruritis in Rare Liver Disease, Alagille Syndrome

-Together with recent positive topline Phase 3 data in progressive familial intrahepatic cholestasis (PFIC), approval underscores maralixibat potential as promising new rare liver disease treatment

-CANbridge holds exclusive Greater China license to maralixibat (CAN108) in  liver diseases, China part of global trial ongoing in biliary atresia (BA)

Dec 20, 2022

CANbridge Pharmaceuticals Announces Orphan Drug Designation Granted to CAN 106 for the Treatment of Myasthenia Gravis

Nov 16, 2022

Article from PhIRDA|Bi Jingquan: To encourage the R&D of drugs for rare diseases, we need to study and formulate special policies that conform to the characteristics of rare diseases

Nov 01, 2022

CANbridge Announces Encouraging Development in Maralixibat/LIVMARLI in Rare Liver Disease

- Congratulates Mirum on Positive Topline Phase 3 Data in progressive familial intrahepatic cholestasis (PFIC)

- CANbridge holds exclusive Greater China license to maralixibat (CAN108) in  liver diseases, China trial ongoing in biliary atresia (BA)

Oct 27, 2022

CANbridge-UMass Chan Medical School Gene Therapy Research in Oral Presentation at the European Society of Gene and Cell Therapy (ESGCT) 29th Annual Congress

Oct 14, 2022

CANbridge Pharmaceuticals to Participate in Upcoming Investor Conferences

Gene Therapy Data to be Presented at the European Society of Gene and Cell Therapy

Oct 13, 2022

CANbridge Pharmaceuticals Data on  CAN106, to be Presented at Two Conferences

Complement C5 Antibody, CAN106, in Phase 1b/2 China Trial in Paroxysmal Nocturnal Hemoglobinuria (PNH)

Sep 22, 2022

CANbridge Pharmaceuticals to Participate in Two Investor Conferences in September

Sep 13, 2022

CANbridge Pharmaceuticals Presented at the Jefferies Asia Forum

Sep 11, 2022

CANbridge Announces Financial Results and Corporate Updates for Six Months Ended June 30, 2022

Aug 24, 2022

First Patient Dosed in CANbridge Pharmaceuticals CAN103 Phase 1/2   Trial for the Treatment of Gaucher Disease in China

Jul 20, 2022

First Patient Dosed in CAN108 (Maralixibat) EMBARK Phase 2 Study in Biliary Atresia in China

  -  China Study is Part of Global EMBARK Study

Jul 14, 2022

CANbridge Forms Scientific Advisory Board to Guide Global Development of CAN106 in Complement-mediated Diseases

Jul 06, 2022

CANbridge Appoints Industry Leader Edward Hu to the Board

Jul 05, 2022

CANbridge CAN106 Phase 1 Data Presented at the European Hematology Association 2022 Congress

Jun 10, 2022

CANbridge Pharmaceuticals to Present at the Jefferies Global Healthcare Conference 2022

Jun 02, 2022

CANbridge Pharmaceuticals to Participate in the Morgan Stanley Virtual China Summit 2022

May 19, 2022

CANbridge-UMass Chan Medical School Gene Therapy Research Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

First Study from CANbridge UMass Collaboration Shows Novel Gene Therapy Holds Promise for Spinal Muscular Atrophy Clinical Applications

May 17, 2022

CANbridge to Present CAN106 Phase 1 Data at the European Hematology Association 2022 Congress

May 13, 2022

Major Breakthrough | China’s National Medical Products Administration potentially to grant new rare disease drugs market exclusivity for up to seven years

May 10, 2022

CANbridge Pharmaceuticals Appoints Pauline Li as Senior Vice President of Clinical Development and Operations

May 09, 2022

CANbridge-UMass Chan Medical School Gene Therapy Research to be Presented at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting

First Study from the CANbridge UMass Chan Medical School Rare Disease Gene Therapy Research Collaboration 

May 04, 2022

CANbridge Pharmaceuticals CAN108 New Drug Application/Orphan Drug Registration (NDA/ORD) for Alagille Syndrome Accepted by the Taiwan Food and Drug Administration

Mar 29, 2022

First Patient Dosed in CAN106 Phase 1b/2 Trial for Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in China

Mar 28, 2022

CANbridge Announces Financial Results and Corporate Updates for the Twelve Months Ended December 31, 2021

Mar 23, 2022

CANbridge Announces Approval of CAN108for Rare Liver Disease, Alagille Syndrome, Under the Early and Pilot Implementation Policy in Boao Lecheng International Medical Tourism Pilot Zone

Feb 25, 2022

CANbridge Pharmaceuticals Appoints

Dr. Lan Hu as New Independent Director

Feb 17, 2022

CANbridge Reports Positive Top-Line CAN106 Phase 1 Data

Receives Approval to Treat Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) in Phase 1b/2 Trial in China

Results Suggest Complete Blockade of Complement Function

CAN106 Safe and Well-Tolerated

Feb 07, 2022

CANbridge Pharmaceuticals CAN108 New Drug Application (NDA), for Alagille Syndrome, Accepted by China’s National Medical Products Administration

Priority Review Expected to be Granted

Jan 18, 2022

Chinese Red Cross Foundation’s Rare Disease Support Fund Officially Launched

Dec 18, 2021

CANbridge Pharmaceuticals Ltd Listed on Main Board of Hong Kong Stock Exchange

Dec 10, 2021

CANbridge and Peking Union Medical College Hospital Agree to Collaborate on Scientific Research for Rare Diseases

Dec 09, 2021

CANbridge Pharmaceuticals Enters into Duchenne Muscular Dystrophy Gene Therapy Research Agreement with University of Washington School of Medicine

Nov 01, 2021

First Patient Dosed in CANbridge Pharmaceuticals CAN008 Phase 2 Trial for Treatment of Glioblastoma Multiforme (GBM) in China

Oct 26, 2021

CANbridge Pharmaceuticals Enters into Exclusive Worldwide Research Collaboration and Licensing Agreement with Scriptr Global for Stitchr™ RNA Assembly Technology to Develop Gene Therapy Product Targeting Dystrophinopathies

CANbridge to Have Exclusive Worldwide Rights to Product

Oct 25, 2021

CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Approved in China for Treatment of Gaucher Disease

Oct 20, 2021

CANbridge Pharmaceuticals CAN103 Investigational New Drug Application Accepted by China’s National Medical Products Administration

Aug 02, 2021

CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in China for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH)

Jul 15, 2021

CANbridge Pharmaceuticals CEO, James Xue, Named as Termeer Foundation Mentor

May 12, 2021

Mirum Pharmaceuticals and CANbridge Pharmaceuticals Enter into Exclusive Licensing Agreement to Develop and Commercialize Maralixibat in Greater China for Rare Liver Diseases

Apr 29, 2021

CANbridge Pharmaceuticals Announces Strategic Collaboration with LogicBio Therapeutics and Licenses to Gene Delivery and Editing Platforms

Apr 27, 2021

First Subject Dosed in CANbridge Pharmaceuticals CAN106 Trial for Treatment of Complement Dysregulation Diseases in Singapore

Mar 10, 2021

CANbridge Pharmaceuticals and Puma Biotechnology Agree to Terminate NERLYNX® License Agreement and Settle Arbitration

Feb 26, 2021

CANbridge Pharmaceuticals Appoints General Manager of China

Dec 22, 2020

CANbridge Pharmaceuticals CAN106 Investigational New Drug Application Approved in Singapore for the Treatment of Complement Dysregulation Diseases

Dec 18, 2020

CANbridge Pharmaceuticals Completes $43 Million Series E Financing

Dec 02, 2020

CANbridge Pharmaceuticals Appoints Head of Global Research

Oct 27, 2020

CANbridge Pharmaceuticals Receives Chinese Marketing Approval for Hunterase® First Enzyme Replacement Therapy for Hunter Syndrome in China

Sep 10, 2020

CANbridge Pharmaceuticals Enters into Second Rare Disease Gene Therapy Research Agreement with UMass Medical School

Sep 09, 2020

CANbridge Pharmaceuticals Receives Marketing Approval for Nerlynx® (Neratinib) in Taiwan

Aug 07, 2020

CANbridge Pharmaceuticals Appoints Senior Vice President/Global Head of Business Development

Jun 16, 2020

CANbridge Pharmaceuticals Enters into Rare Disease Gene Therapy Research Agreement with UMass Medical School

Jun 09, 2020

CANbridge Pharmaceuticals Receives Marketing Approval for Nerlynx® (Neratinib) in China

May 14, 2020

CANbridge Pharmaceuticals Completes US$98 Million Series D Financing

Feb 19, 2020

Shanghai Foundation for Rare Disease Appoints CANbridge CEO, James Xue, Deputy Director General Sole Representative from the Pharmaceutical Industry

Jan 06, 2020

CANbridge Receives Hong Kong Department of Health Market Approval for Nerlynx®

Nov 05, 2019

CANbridge Pharmaceuticals’ Hunterase® Granted Priority Review by the Chinese National Medical Products Administration

Sep 09, 2019

CANbridge Pharmaceuticals Appoints Senior Vice President, Rare Disease Commercial Operations

Jul 30, 2019

CANbridge Pharmaceuticals Submits New Drug Application for Hunterase® for the Treatment of Hunter Syndrome in China

Jul 29, 2019

CANbridge Pharmaceuticals Appoints Chief Financial Officer and Interim Chief Medical Officer

Apr 25, 2019

CANbridge Pharmaceuticals and WuXi Biologics Expand Rare Disease Therapeutics Partnership

Jan 08, 2019

CANbridge Pharmaceuticals and GC Pharma Announce Greater China Licensing Agreement for Hunterase™ for Hunter Syndrome

Jan 07, 2019

CANbridge Pharmaceutical and WuXi Biologics Enter into Strategic Partnership for Rare Disease Therapeutics

Oct 23, 2018

CANbridge Life Sciences Receives Approval to Commence CAN017 Ib/III Trial in Esophageal Squamous Cell Cancer (ESCC) in China

Aug 14, 2018

CANbridge Life Sciences Appoints Chief Medical Officer

Jul 31, 2018

CANbridge Life Sciences Appoints Vice President of Clinical Development and Medical Affairs and Director of Quality Assurance

May 08, 2018

CANbridge Receives China Food and Drug Administration Approval for CAN002 as Cancer Adjuvant Therapy

Apr 26, 2018

CANbridge Receives Approval to Commence CAN008 Phase II/III Trial in Glioblastoma Multiforme (Gbm) in China

Apr 12, 2018

Industry Veteran Joins CANbridge Life Sciences Advisory Team

Feb 13, 2018

Puma Biotechnology and CANbridge Life Sciences Enter into Exclusive Licensing Agreement to Commercialize Nerlynx® (Neratinib) in Greater China

Feb 02, 2018

CANbridge Appoints Sunny Zhang as Vice President of Regulatory Affairs and Quality

Jan 16, 2018

CANbridge Life Sciences Submits Investigational New Drug Application for CAN017 Trial in Esophageal Squamous Cell Cancer (ESCC) in China

Dec 21, 2017

CANbridge Completes Patient Enrolment for Phase I Clinical Trial of CAN008 in Treatment of Glioblastoma Multiforme in Taiwan

Nov 30, 2017

CAN008 Injection for the Treatment of Gbm China Taiwan Phase I Data Releasing

Nov 02, 2017

James Xue is Appointed to Leadership and Development Council Member

Sep 26, 2017

CANbridge Life Sciences Appoints Chief Business Officer Will Head First US Office

Sep 12, 2017

CANbridge Congratulates Apogenix APG101 Receiving Ema “Prime” Designation

Jul 26, 2017

CANbridge Submits Ind Application for CAN008 PHII/III Trial in GBM in China

Jul 18, 2017

James Xue, Founder and CEO of CANbridge, Present at 2017 China GCP Conference

Jun 08, 2017

James Xue, Founder and CEO of CANbridge, Present at 2017 Boston CEO Conference

Jun 01, 2017

CANbridge Life Sciences Raises $25 Million in Series B Round Led by Lapam Capital

May 23, 2017

CANbridge Life Sciences and Amoy Diagnostics Announced that They Have Entered into a Strategic Partnership to Develop a Companion Diagnostic Assay for Canbridge’s Lead Candidate, CAN008, a Fully Human FC Fusion Protein.

May 08, 2017

CANbridge Life Sciences Awarded “Deal of the Year 2016 ”by China Healthcare Investment Conference for License of Cancer Candidate from AVEO

Mar 31, 2017

First Patient Dosed in CANbridge’s CAN-008 Phase I/II Trial in Newly-diagnosed Glioblastoma Multiforme in Taiwan First CANbridge Clinical Trial

Sep 26, 2016

CANbridge Signs Agreement with Boehringer Ingelheim to Manufacture Inhibitory Antibody,CAN-017,for Esophageal Squamous Cell Cancer

Aug 11, 2016

CANbridge’s CAN-008 Approved for Phase I/II Trial in Newly-Diagnosed Glioblastoma Multiforme in Taiwan

Jul 26, 2016

CANbridge Appoints Dr. Huai Zhong Hu as Vice President of Preclinical Development

Jul 05, 2016

CANbridge Life Sciences ltd. Elected to be a Member of Phirda

Jun 03, 2016

James Xue, Founder and CEO of CANbridge, Present at 2016 Boston CEO Conference

May 29, 2016

CANbridge Submits Investigational New Drug Application to Taiwan Food and Drug Administration for CAN-008 Phase I/II Trial in Glioblastoma Selects WuXi Biologics to Manufacture CAN-008 for the China Market

Apr 07, 2016

AVEO and CANbridge Life Sciences Announce Exclusive Licensing Agreement for AV-203 Outside of North America

Mar 22, 2016

CANbridge Completes Chinese Glioblastoma Biomarker Study for Lead Candidate, CAN008 Plans to Initiate Phase I/II Trial in Taiwan in 2016

Jan 11, 2016

James Xue,Founder and CEO of CANbridge,to Present at 2016 East West CEO Conference

Dec 17, 2015

CANbridge Appoints Mark A. Goldberg as Acting Chief Medical Officer Raises Additonal Capital in Series a Plus Round

Oct 22, 2015

CANbridge Acquires License for Apogenix’s APG101 Onco-immunotherapy in Glioblastoma for China

Jul 16, 2015

CANbridge Life Sciences, Inc. Joins the Medtech Group

Apr 08, 2015

CANbridge Life Sciences Ceo,James Xue, Presenting at Cancer Advanced Boston and Boston CEO

Apr 02, 2015

James Xue, Founder and CEO of CANbridge, to Present at 2015 East West CEO Conference

Dec 15, 2014

CANbridge Life Sciences Raises $10 Million in Series a Round Led by Qiming Venture Partners

Dec 03, 2014

James Xue, Founder and CEO of CANbridge to Attend Cancer Advance Boston Conference

Sep 28, 2014

CANbridge Life Sciences and EUSA Pharma form Agreement to Commericialize Caphosol® in China

Jul 28, 2014

CANbridge Certified Frontier Oncology Diagnosis & Treatment International Collaboration Base by Beijing Municipal Commission of Science and Technology

Mar 14, 2014

CANbridge Featured in Biocentury

Feb 18, 2014

James Xue, Founder and CEO of CANbridge Recognized by “Chaoyang Phoenix High-caliber Overseas Talents 2013”

Jan 14, 2014

CANbridge to Present at Biotech Showcase™ 2014

Dec 16, 2013

CANbridge CEO Featured at Peking University Alumni Forum

Nov 22, 2013

CANbridge Certified Golden Seed Enterprise by Administrative Committee of Zhongguancun Science Park

Nov 18, 2013

An In-depth Interview with James Xue, CEO of CANbridge, by Pharmatimes

Oct 08, 2013

CANbridge-azaya Deal Featured in Bioworld Today

Oct 05, 2013

CANbridge Life Sciences Announces Advisory Board Memembers

Sep 26, 2013

CANbridge Enters Into Agreement with Azaya to Develop Anti-cancer Drug ATI-1123

Sep 11, 2013